蒲公英 - 制药技术的传播者 GMP理论的实践者

搜索
查看: 1911|回复: 1
收起左侧

[质量保证QA] 关于data integrity在委托实验室和校验单位的管理

[复制链接]
药士
发表于 2016-10-2 09:36:46 | 显示全部楼层 |阅读模式

欢迎您注册蒲公英

您需要 登录 才可以下载或查看,没有帐号?立即注册

x
本帖最后由 beiwei5du 于 2016-10-2 09:40 编辑

各位蒲友:


在中国CFDA最近公布的《药品数据管理规范》(征求意见稿)中均有提到相应的委托(外包)工作的范畴:
第二条【范围】本规范适用于药品研制、生产、流通等活动,包括从事上述活动的临床试验、合同研究(CRO)、委托生产(CMO)、委托检验等单位和个人。(没有包括委托校准和委托IT数据管理)
WHO good data and record management中也提及到:
The organization outsourcing work has responsibility for the integrity of all results reported, including those furnished by any subcontracting organization or service provider. These responsibilities extend to any providers of relevant computing services, such as contracted IT data centres, contracted IT system and database support personnel and cloud computing solution providers.

及其他一些课件(爱尔兰HPRA):data integrity: a regulator' perspective http://www.it-asso.com/gxp/files/HPRA_DataInteg_150512.pdf
Inspection focus
•EU Regulatory Requirements – Part I Chapter 4 and Annex 11 and Part II
•Data integrity requirements applicable to:
–API and FP manufacturers, including contract manufacturing
–Testing units, including contract laboratories
–Outsourced GMP activities such as equipment qualification and calibration

那么对于委托检验和委外校验的监管的数据完整性也是需要极其重视的一个方面,这方面国家没有重视起来,配套机构的数据完整性还是很关键的。

本帖被以下淘专辑推荐:

回复

使用道具 举报

药士
 楼主| 发表于 2016-10-3 14:57:01 | 显示全部楼层
现在很多公司在委托实验室和委托校验的时候,仅仅出具相应的检测报告和校准报告是不合适的,下文有谈到summary report的局限的问题(这个也即是我们的检测报告和校准报告的缺陷)8.12 Limitations of remote review of summary reports
8.12.1 The remote review of data within summary reports is a common necessity; however, the limitations of remote data review must be fully understood to enable adequate control of data integrity.
8.12.2 Summary reports of data are often supplied between physically remote manufacturing sites, Market Authorisation Holders and other interested parties.However, it must be acknowledged that summary reports are essentially limited in their nature, in that critical supporting data and metadata is often not included and therefore original data cannot be reviewed.
8.12.3 It is therefore essential that summary reports are viewed as but one element of the process for the transfer of data and that interested parties and inspectorates do not place sole reliance on summary report data.
8.12.4 Prior to acceptance of summary data, an evaluation of the supplier’s quality system and compliance with data integrity principles should be established through on-site inspection when considered important in the context of quality risk management. The inspection should ensure the veracity of data generated by the company, and include a review of the mechanisms used to generate and distribute summary data and reports.

回复

使用道具 举报

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

×发帖声明
1、本站为技术交流论坛,发帖的内容具有互动属性。您在本站发布的内容:
①在无人回复的情况下,可以通过自助删帖功能随时删除(自助删帖功能关闭期间,可以联系管理员微信:8542508 处理。)
②在有人回复和讨论的情况下,主题帖和回复内容已构成一个不可分割的整体,您将不能直接删除该帖。
2、禁止发布任何涉政、涉黄赌毒及其他违反国家相关法律、法规、及本站版规的内容,详情请参阅《蒲公英论坛总版规》。
3、您在本站发表、转载的任何作品仅代表您个人观点,不代表本站观点。不要盗用有版权要求的作品,转贴请注明来源,否则文责自负。
4、请认真阅读上述条款,您发帖即代表接受上述条款。

QQ|手机版|蒲公英|ouryao|蒲公英 ( 京ICP备14042168号-1 )  京ICP证150354号  互联网药品信息服务证书编号: (京)-非经营性-2024-0033

GMT+8, 2024-11-13 00:48

Powered by Discuz! X3.4运维单位:苏州豚鼠科技有限公司

Copyright © 2001-2020, Tencent Cloud.

声明:蒲公英网站所涉及的原创文章、文字内容、视频图片及首发资料,版权归作者及蒲公英网站所有,转载要在显著位置标明来源“蒲公英”;禁止任何形式的商业用途。违反上述声明的,本站及作者将追究法律责任。
快速回复 返回顶部 返回列表